Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organicell Regenerative Medicine Inc (OP: OCEL )

0.0115 UNCHANGED
Streaming Delayed Price Updated: 12:45 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Organicell Regenerative Medicine Inc

Recent Report Shows That Extracellular Vesicles Might Also Be Key To Stopping COVID, Colds, And Other Nasal Viruses
By Rachael Green, Benzinga 
Via News Direct
Exposures COVID-19 Product Safety
Recent Report Shows That Extracellular Vesicles Might Also Be Key To Stopping COVID, Colds, And Other Nasal Viruses
To learn more about Organicell, download the latest research report here 
Via TheNewswire.com
Exposures COVID-19 Product Safety
Recent Report Shows That Extracellular Vesicles Might Also Be Key To Stopping COVID, Colds, And Other Nasal Viruses
To learn more about Organicell, download the latest research report here 
Via Benzinga
Organicell Regenerative Medicine, Inc. Responds to Recent Promotional Activities Pursuant to OTC Markets Request
Via ACCESSWIRE
Organicell Starts Enrolling Long COVID Trial
Via ACCESSWIRE
Organicell Activates COPD Trial at Mayo Clinic
Via ACCESSWIRE
Organicell Regenerative Medicine, Inc. Announces Additions to Board of Directors
Via ACCESSWIRE
Organicell Regenerative Medicine, Inc. Announces Expansion into Health and Beauty Market
 
Via Benzinga
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body.... 
Via FinancialNewsMedia
Exposures COVID-19
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END 
Via FinancialNewsMedia
Organicell Regenerative Medicine Broadens Access to Valued Business Expertise and Relationship With New Additions to Board of Directors
Organicell Regenerative Medicine, Inc. (OTCQB: OCEL) recently announced that the Company has added independent board members to its board of directors. 
Via Benzinga
Organicell Regenerative Medicine, Inc. Announces Expansion of Management Team
Via ACCESSWIRE
Pharma Company Organicell Partners With Beauty Health Focusing On Aging & Inflammation Signs
 
Via Benzinga
Organicell Regenerative Medicine, Inc. Announces Expansion into Health and Beauty Market
Via ACCESSWIRE
BeautyHealth’s Hydrafacial Announces Partnership to Develop Breakthrough Exosome Booster
From BeautyHealth
Via Business Wire
Organicell Regenerative Medicine, Inc. Secures Additional $11 Million in Financing in Preparation for Clinical Trial Enrollment
Via ACCESSWIRE
Organicell Regenerative Medicine, Inc. Engages Law Firm McDermott Will & Emery
Via ACCESSWIRE
Organicell Regenerative Medicine, Inc. Closes $5.5 Million Funding Round
Via ACCESSWIRE
Organicell Announces Matt Sinnreich as CEO
Via ACCESSWIRE
Organicell Announces Matt Sinnreich as CEO
MIAMI, FL / ACCESSWIRE / July 26, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological... 
From Organicell Regenerative Medicine, Inc.
Via AccessWire
Topics Derivatives
Exposures Derivatives
Organicell Regenerative Medicine, Inc. Secures $4 Million in Funding for Clinical Trials and Agrees To Restructure Management
Via ACCESSWIRE
Organicell Regenerative Medicine, Inc. Secures $4 Million in Funding for Clinical Trials and Agrees To Restructure Management
MIAMI, FL / ACCESSWIRE / July 20, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological... 
From Organicell Regenerative Medicine, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Organicell And Proxima CRO Set To Open Clinical Trial For Long Hauler COVID-19 Patients
MIAMI, FL / ACCESSWIRE / February 8, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies,... 
From Organicell Regenerative Medicine
Via AccessWire
Exposures COVID-19
Organicell Regenerative Medicine, Inc. Provides Updates of Clinical Trial Activities
MIAMI, FL / ACCESSWIRE / December 29, 2021 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, is... 
From Organicell Regenerative Medicine, Inc.
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.